Montelukast: Data from clinical trials in the management of asthma

Annals of Pharmacotherapy

Volumn 33, Issue 12, 1999, Pages 1299-1314

  Blake, Kathryn V ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Adherence; Asthma; Cysteinyl leukotriene receptor antagonist; Eosinophil; Montelukast

Indexed keywords

CORTICOSTEROID; MONTELUKAST;

ASTHMA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUNG FUNCTION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033401342     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18430     Document Type: Review

References (97)

1. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1995;10:94.
2. Surveillance for asthma - United States, 1960-1995. MMWR Morb Mortal Wkly Rep 1998;47:1-26.
3. Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults - United States, 1990-1993. MMWR Morb Mortal Wkly Rep 1996;45:350-3.
4. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma: quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145(4, pt 1):890-9.
5. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperactivity. Am Rev Respir Dis 1989;140:1745-53.
6. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156 (3, pt 1):737-43.
7. National Heart, Lung, and Blood Institute, National Asthma Education Program, Expert Panel Report II. Guidelines for the diagnosis and management of asthma. Pub. no. 97-4051. Bethesda, MD: US Department of Health and Human Services, 1997.
8. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
9. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-52.
10. Boot AM, de Jangste JC, Verberne AAPH, Pois HAP, de Muinck Keizer-Schrama SMPF. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroid. Pediatr Pulmonol 1997;24:379-84.
11. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate - Salmeterol Xinofoate Study Group. N Engl J Med 1997;337:1659-65.
12. Crowley S, Trivedi P, Risteli L, Risteli J, Hindmarsh PC, Brook CG. Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr 1998;132:409-13.
13. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 1995;23:283-5.
14. Henderson ER. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
15. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
16. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
17. Harris RR, Carter GW, Bell RL, Moore JL, Brooks DW. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol 1995;17:147-56.
18. Holgate ST, Bradding BM, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
19. Barnes NC, Luitert LM. Drugs affecting the leukotriene pathway in asthma. Br J Clin Pract 1995;49:262-6.
20. Dahlen S, Kumlin M, Bjorck T, Raud J, Hedqvist P. Airway smooth muscle and disease workshop: leukotrienes and related eicosanoids. Am Rev Respir Dis 1987;136(4 pt 2):S24-8.
21. 4 elimination and metabolism in man. J Allergy Clin Immunol 1990;85:3-9.
22. Gross NJ. Leukotriene modifiers: what place in asthma management? J Respir Dis 1998;19:245-61.
23. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
24. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997;127:472-80.
25. M Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
26. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997; 61:83-92.
27. 4 receptor antagonist. Can J Physiol Pharmacol 1995;73: 191-201.
28. 1 receptor. Nature 1999;399:789-93.
29. Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Molecular Pharmacology 1999;56:657-63.
30. Cheng H, Leff JA, Amin R, Gertz BJ, De Smit M, Noonan N, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996;13:445-8.
31. 4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995;40:277-80.
32. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997;18:769-77.
33. 1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997;25:1282-7.
34. Altman LC, Munk Z, Seltzer J, Noonan N, Shinge S, Zhang J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-6.
35. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBumey J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11:1232-9.
36. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556-61.
37. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year-old children with asthma. J Pediatr 1998;133: 424-8.
38. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
39. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment (abstract). Eur Respir J 1997;10(suppl 25):437s.
40. Knorr B, Nguyen H, Villaran C, Kearns G, Boza M, Rogers J, et al. Selection of a montelukast dose in 2- to 5-year-olds by a comparison of pediatric and adult single-dose population pharmacokinetic (PK) profiles (abstract). Clin Pharmacol Ther 1998;63:191A.
41. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998;279:1181-6.
42. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20.
43. Reiss TF, Chervinsky P, Noonan M, Prenner B, Zhang J, Hess J, et al. MK-0476, an LTD-4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma (abstract). Eur Respir J Suppl 1995;19:289s.
44. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei L, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999;130:487-95.
45. Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999;104: 547-53.
46. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
47. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
48. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998;158:36-41.
49. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8.
50. Package insert. Flovent (flutioasone). Research Triangle Park, NC: Glaxo Wellcome, 1999.
51. Turpin JA, Edelman JM, DeLucca PT, Pearlman DS. Chronic administration of montelukast (MK-0476) is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction (EIB) (abstract). Am J Respir Crit Care Med 1998;157:A456.
52. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999;29:42-51.
53. 1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients (abstract). Am J Respir Crit Care Med 1997;155:A975.
54. O'Connor BJ, Godard P, Dube LM, Swanson LJ, Rountree LV, the European Zileuton Study Group. The effect of a 5-lipoxygenase inhibitor, zileuton, plus a low-dose inhaled beclomethasone alone in patients with asthma (abstract). Am J Respir Crit Care Med 1996;153:A803.
55. Nayak AS, Anderson PJ, Charous BL, Williams KL, Miller CJ, Bonuccelli CM, et al. Addition of zafirlukast compared with a doubled dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids (abstract). Eur Respir J Suppl 1998;12(suppl 28): 361S.
56. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, Lofdahl CG, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability (abstract). Am J Respir Crit Care Med 1997;155:A976.
57. Crocker IC, Zhou CY, Bewtra AK, Kreutner W, Townley RG. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997;78:497-505.
58. Dworski R, Fitzgerald GA, Dates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
59. Noonan G, Reiss TF, Shingo S, Nguyen HH, Knorr B. Montelukast (MK-0476) maintains long-term asthma control in adult and pediatric patients (aged ≥6 years). Am J Respir Crit Care Med 1999;159:A640.
60. Malmstrom K, Meltzer E, Prenner B, Lu S, Weinstein S, Wolfe J, et al. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis (abstract). J Allergy Clin Immunol 1998;101(suppl):S97.
61. Gustafsson LE. Exhaled nitric oxide as a marker in asthma. Eur Respir J 1998;26(suppl):49S-52S.
62. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
63. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160:1227-31.
64. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
65. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999;353: 725-6.
66. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest 1995;108:320-3.
67. 4 receptor antagonist, in humans. Drug Metab Dispos 1997;25:1022-31.
68. Holland S, Shahane A, Rogers JD, Porras A, Grasing K, Lasseter K, et al. Metabolism of montelukast (M) is increased by multiple doses of phenobarbital (abstract). Clin Pharmacol Ther 1998;63:231A.
69. 4 receptor antagonist, montelukast (M), on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations (abstract). Clin Pharmacol Ther 1997;61:162.
70. Holland S, Gertz B, Desmet M, Michiels N, Larson P, Freeman A, et al. Montelukast has no effect on terfenadine pharmacokinetics or QTc (abstract). Clin Pharmacol Ther 1998;63:232A.
71. Malmstrom K, Schwartz J, Reiss TF, Sullivan TJ, Reese JH, Jauregui L, et al. Effect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther 1998;5:189-95.
72. Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999; 39:495-500.
73. Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, et al. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. Clin Pharmucokinet 1995;29 (suppl 2):49-61.
74. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-81.
75. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkleman DG, Vandewalker ML, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998;132:472-7.
76. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med 1998;157:178-83.
77. FDA requires new pediatric labeling for inhaled, intranasal corticosteroids. FDA Talk Paper. Bethesda, MD: Food and Drug Administration, November 9, 1998.
78. Garbe E, LeLorier J, Bolvin J-F, Suissa S. Inhaled and nasal glucocorticosteroids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.
79. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
80. Garbe E. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539-43.
81. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-6.
82. Ledford D, Apter A, Manon Brenner A, Rubin K, Prestwood K, Frieri M, et al. Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol 1998;102:353-62.
83. Verberne AAPH, Fuller R. An overview of nine clinical trials of salmeterol in an asthmatic population. Respir Med 1998;92:777-82.
84. Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998;157: 184-91.
85. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
86. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65-9.
87. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;339:141-6.
88. Hansen-Flaschen J, Schotland H. New treatments for exercise-induced asthma (editorial). N Engl J Med 1998;339:192.
89. Giannini D, Carletti A, Dente FL, Bacci E, DiFranco A, Vagaggini B, et al. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996;110:1452-7.
90. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 1998;80:31-4.
91. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-7.
92. Casale TB. Compliance and oral therapy for asthma. Allergy Clin Immunol Int 1997;9:72-8.
93. Coutts JAP, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992;67:332-3.
94. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J 1995;8:899-904.
95. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6, pt 1):1051-7.
96. Ringdal N, Whitney JG, Summerton L. Problems with inhaler technique and patient preference for oral therapy - tablet zafirlukast vs. inhaled beclomethasone (abstract). Am J Respir Crit Care Med 1998;157:A416.
97. Virchow JC, Hassal SM, Summerton L, Harris A. Improved asthma control over 6 weeks with Accolate (zafirlukast) in patients on high-dose inhaled corticosteroids (abstract). J Investig Med 1997;45:286A.